Overview

Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children

Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the clinical efficacy and safety of the modified Qing-Ying Decoction (mQYD) for the treatment of subacute and chronic atopic dermatitis (AD) in children when compared to the placebo control through examining the clinical symptoms, quality of life, gut microbiome, and Chinese medicine body constitution. This is a parallel, randomized, placebo-controlled, double-blind clinical trial. Eligible subjects will be randomly allocated to receive oral mQYD granules or it's placebo granules. Subjects will have 12-week of treatment, and then a 4-week follow-up.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Chinese University of Hong Kong